Opioid use disorder.


Journal

Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103

Informations de publication

Date de publication:
09 01 2020
Historique:
accepted: 20 11 2019
entrez: 11 1 2020
pubmed: 11 1 2020
medline: 3 2 2021
Statut: epublish

Résumé

Opioid use disorder (OUD) is a chronic relapsing disorder that, whilst initially driven by activation of brain reward neurocircuits, increasingly engages anti-reward neurocircuits that drive adverse emotional states and relapse. However, successful recovery is possible with appropriate treatment, although with a persisting propensity to relapse. The individual and public health burdens of OUD are immense; 26.8 million people were estimated to be living with OUD globally in 2016, with >100,000 opioid overdose deaths annually, including >47,000 in the USA in 2017. Well-conducted trials have demonstrated that long-term opioid agonist therapy with methadone and buprenorphine have great efficacy for OUD treatment and can save lives. New forms of the opioid receptor antagonist naltrexone are also being studied. Some frequently used approaches have less scientifically robust evidence but are nevertheless considered important, including community preventive strategies, harm reduction interventions to reduce adverse sequelae from ongoing use and mutual aid groups. Other commonly used approaches, such as detoxification alone, lack scientific evidence. Delivery of effective prevention and treatment responses is often complicated by coexisting comorbidities and inadequate support, as well as by conflicting public and political opinions. Science has a crucial role to play in informing public attitudes and developing fuller evidence to understand OUD and its associated harms, as well as in obtaining the evidence today that will improve the prevention and treatment interventions of tomorrow.

Identifiants

pubmed: 31919349
doi: 10.1038/s41572-019-0137-5
pii: 10.1038/s41572-019-0137-5
doi:

Substances chimiques

Narcotic Antagonists 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3

Subventions

Organisme : Department of Health
ID : 12/136/105
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0616-20008
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : P20 GM125507
Pays : United States

Références

Blanco, C. & Volkow, N. D. Management of opioid use disorder in the USA: present status and future directions. Lancet 393, 1760–1772 (2019).
pubmed: 30878228 doi: 10.1016/S0140-6736(18)33078-2
Strang, J. et al. Drug policy and the public good: evidence for effective interventions. Lancet 379, 71–83 (2012).
pubmed: 22225672 doi: 10.1016/S0140-6736(11)61674-7
Babor, T. et al. Drug Policy and the Public Good 2nd edn (Oxford Univ. Press, 2018).
Marsden, J. et al. Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial. Lancet Psychiatry 6, 391–402 (2019).
pubmed: 30952568 doi: 10.1016/S2215-0366(19)30097-5
Barocas, J. A. et al. Estimated prevalence of opioid use disorder in massachusetts, 2011-2015: a capture-recapture analysis. Am. J. Public Health 108, 1675–1681 (2018).
pubmed: 30359112 pmcid: 6236756 doi: 10.2105/AJPH.2018.304673
Bose, J., Hedden, S. L., Lipari, R. N. & Park-Lee, E. Key substance use and mental health indicators in the United States: results from the 2017 national survey on drug use and health (SAMHSA, 2017).
Degenhardt, L. et al. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend. 117, 85–101 (2011).
pubmed: 21377813 doi: 10.1016/j.drugalcdep.2010.11.032
Vos, T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1211–1259 (2017).
doi: 10.1016/S0140-6736(17)32154-2
Khademi, H. et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50 000 adults in Iran. BMJ 344, e2502 (2012).
pubmed: 22511302 pmcid: 3328545 doi: 10.1136/bmj.e2502
Malekinejad, M. & Vazirian, M. Transition to injection amongst opioid users in Iran: Implications for harm reduction. Int. J. Drug. Policy 23, 333–337 (2012).
pubmed: 21996166 doi: 10.1016/j.drugpo.2011.09.001
Razani, N. et al. HIV risk behavior among injection drug users in Tehran, Iran. Addiction 102, 1472–1482 (2007).
pubmed: 17645427 doi: 10.1111/j.1360-0443.2007.01914.x
Frenk, S. M., Porter, K. S. & Paulozzi, L. J. Prescription opioid analgesic use among adults: United States, 1999-2012. NCHS Data Brief 189, 1–8 (2015).
Dart, R. C. et al. Trends in opioid analgesic abuse and mortality in the United States. N. Engl. J. Med. 372, 241–248 (2015).
pubmed: 25587948 doi: 10.1056/NEJMsa1406143
Han, B. et al. Prescription opioid use, misuse, and use disorders in u.s. adults: 2015 national survey on drug use and health. Ann. Intern. Med. 167, 293–301 (2017).
pubmed: 28761945 doi: 10.7326/M17-0865
Jones, C. M. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers – United States, 2002–2004 and 2008–2010. Drug Alcohol Depend. 132, 95–100 (2013).
pubmed: 23410617 doi: 10.1016/j.drugalcdep.2013.01.007
Martins, S. S. et al. Changes in US lifetime heroin use and heroin use disorder: prevalence from the 2001-2002 to 2012-2013 national epidemiologic survey on alcohol and related conditions. JAMA Psychiatry 74, 445–455 (2017).
pubmed: 28355458 pmcid: 5470460 doi: 10.1001/jamapsychiatry.2017.0113
Rubin, R. Illicit fentanyl driving opioid overdose deaths. JAMA 318, 2174–2174 (2017).
pubmed: 29234816
Nutt, D., King, L. A., Saulsbury, W. & Blakemore, C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 369, 1047–1053 (2007).
pubmed: 17382831 doi: 10.1016/S0140-6736(07)60464-4
Kreek, M. J. et al. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J. Clin. Invest. 122, 3387–3393 (2012).
pubmed: 23023708 pmcid: 3534165 doi: 10.1172/JCI60390
Zinberg, N. E. & Jacobson, R. C. The natural history of “chipping”. Am. J. Psychiatry 133, 37–40 (1976).
pubmed: 1247121 doi: 10.1176/ajp.133.1.37
Hser, Y. I., Hoffman, V., Grella, C. E. & Anglin, M. D. A 33-year follow-up of narcotics addicts. Arch. Gen. Psychiatry 58, 503–508 (2001). This seminal natural history paper shows both the important contribution of longitudinal observational cohort studies and also the captures the scale of morbidity and mortality associated with opioid use.
pubmed: 11343531 doi: 10.1001/archpsyc.58.5.503
Sordo, L. et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 357, j1550 (2017).
pubmed: 28446428 pmcid: 5421454 doi: 10.1136/bmj.j1550
Merrall, E. L. et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction 105, 1545–1554 (2010).
pubmed: 20579009 pmcid: 2955973 doi: 10.1111/j.1360-0443.2010.02990.x
Kimber, J., Larney, S., Hickman, M., Randall, D. & Degenhardt, L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry 2, 901–908 (2015).
pubmed: 26384619 doi: 10.1016/S2215-0366(15)00366-1
Sweeting, M. J., De Angelis, D., Ades, A. E. & Hickman, M. Estimating the prevalence of ex-injecting drug use in the population. Stat. Methods Med. Res. 18, 381–395 (2009).
pubmed: 19036912 doi: 10.1177/0962280208094704
De Angelis, D., Hickman, M. & Yang, S. Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am. J. Epidemiol. 160, 994–1004 (2004).
pubmed: 15522856 doi: 10.1093/aje/kwh306
Gfroerer, J. & Brodsky, M. The incidence of illicit drug use in the United States, 1962-1989. Br. J. Addict. 87, 1345–1351 (1992).
pubmed: 1392556 doi: 10.1111/j.1360-0443.1992.tb02743.x
Termorshuizen, F. et al. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam cohort study among drug users. Drug Alcohol Depend. 79, 231–240 (2005).
pubmed: 16002032 doi: 10.1016/j.drugalcdep.2005.01.013
Shah, N. G., Galai, N., Celentano, D. D., Vlahov, D. & Strathdee, S. A. Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. Drug Alcohol Depend. 83, 147–156 (2006).
pubmed: 16364568 doi: 10.1016/j.drugalcdep.2005.11.007
Kimber, J. et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 341, c3172 (2010).
pubmed: 20595255 pmcid: 2895695 doi: 10.1136/bmj.c3172
Mehta, S. H. et al. Factors associated with injection cessation, relapse and initiation in a community-based cohort of injection drug users in Chennai, India. Addiction 107, 349–358 (2012). This paper explores these important factors in OUD development and progression in different contexts from most published papers, and shows the importance of studying opioid users in countries outside historically wealthy countries – especially low and middleincome countries.
pubmed: 21815960 doi: 10.1111/j.1360-0443.2011.03602.x
Hser, Y. I., Huang, D., Chou, C. P. & Anglin, M. D. Trajectories of heroin addiction: growth mixture modeling results based on a 33-year follow-up study. Eval. Rev. 31, 548–563 (2007).
pubmed: 17986707 doi: 10.1177/0193841X07307315
Degenhardt, L. et al. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376, 285–301 (2010).
pubmed: 20650522 doi: 10.1016/S0140-6736(10)60742-8
Saha, T. D. et al. Nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder in the United States. J. Clin. Psychiatry 77, 772–780 (2016).
pubmed: 27337416 pmcid: 5555044 doi: 10.4088/JCP.15m10386
Nelson, E. C. et al. Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addict. Biol. 19, 111–121 (2014).
pubmed: 22500942 doi: 10.1111/j.1369-1600.2012.00445.x
Dowell, D., Haegerich, T. M. & Chou, R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. MMWR Recomm. Rep. 65, 1–49 (2016).
pubmed: 26987082 doi: 10.15585/mmwr.rr6501e1
Dowell, D., Haegerich, T. M. & Chou, R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. JAMA 315, 1624–1645 (2016).
pubmed: 26977696 pmcid: 6390846 doi: 10.1001/jama.2016.1464
Degenhardt, L. et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet 394, 1560–1579 (2019). This global review takes illustrative examples of three very different parts of the world and, starting with data from the Global Burden of Disease and then applying mathematic modelling, identifies the general benefit of provision of treatment and the particular effectiveness of OAT, and yet finding that the coverage of these interventions remains low, even in high-income countries.
pubmed: 31657732 doi: 10.1016/S0140-6736(19)32229-9
Paulozzi, L. J., Mack, K. A. & Hockenberry, J. M. Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines – United States, 2012. MMWR Morb. Mortal. Wkly Rep. 63, 563–568 (2014).
pubmed: 24990489 pmcid: 4584903
Kolodny, A. et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu. Rev. Public Health 36, 559–574 (2015).
pubmed: 25581144 doi: 10.1146/annurev-publhealth-031914-122957
Dowell, D., Haegerich, T. M. & Chou, R. CDC guideline for prescribing opioids for chronic pain. MMWR Morb. Mortal. Wkly Rep. 65, 1–49 (2016).
Hadland, S. E., Cerda, M., Li, Y., Krieger, M. S. & Marshall, B. D. L. Association of pharmaceutical industry marketing of opioid products to physicians with subsequent opioid prescribing. JAMA Intern. Med. 178, 861–863 (2018).
pubmed: 29799955 pmcid: 6145750 doi: 10.1001/jamainternmed.2018.1999
Hadland, S. E., Rivera-Aguirre, A., Marshall, B. D. L. & Cerda, M. Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses. JAMA Netw. Open. 2, e186007 (2019).
pubmed: 30657529 pmcid: 6484875 doi: 10.1001/jamanetworkopen.2018.6007
Davis, C. S. & Carr, D. H. Self-regulating profession? Administrative discipline of “pill mill” physicians in Florida. Subst. Abus. 38, 265–268 (2017).
pubmed: 28394740 doi: 10.1080/08897077.2017.1316812
Centers for Disease Control and Prevention. Multiple cause of death data (CDC, 2016).
US National Center for Health Statistics. United States, 2014: with special feature on adults aged 55–64 (CDC, 2015).
US National Center for Health Statistics. United States, 2015: in brief (CDC, 2016).
Compton, W. M. & Volkow, N. D. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. 83, S4–S7 (2006).
pubmed: 16563663 doi: 10.1016/j.drugalcdep.2005.10.020
Amin-Esmaeili, M. et al. Epidemiology of illicit drug use disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian mental health survey. Addiction 111, 1836–1847 (2016).
pubmed: 27177849 doi: 10.1111/add.13453
Ford, J. A. & Rigg, K. K. Racial/ethnic differences in factors that place adolescents at risk for prescription opioid misuse. Prev. Sci. 16, 633–641 (2015).
pubmed: 25344348 doi: 10.1007/s11121-014-0514-y
Lascala, E., Friesthler, B. & Gruenwald, P. J. in Preventing Harmful Substance Use: The Evidence Base for Policy and Practice (eds Stockwell, T., Gruenwald, P., Toumbourou, J. & Loxley, W.) (John Wiley & Sons, 2005).
Fergusson, D. M., Boden, J. M. & Horwood, L. J. The developmental antecedents of illicit drug use: evidence from a 25 year longitudinal study. Drug Alcohol Depend. 96, 167–177 (2008).
doi: 10.1016/j.drugalcdep.2008.03.003
Hawkins, J., Catalano, R. & Miller, J. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychological Bull. 112, 64–105 (1992).
doi: 10.1037/0033-2909.112.1.64
Daniel, J. Z. et al. Is socioeconomic status in early life associated with drug use? A systematic review of the evidence. Drug Alcohol Rev. 28, 142–153 (2009).
pubmed: 19320699 doi: 10.1111/j.1465-3362.2008.00042.x
Cohen, D. A., Richardson, J. & LaBree, L. Parenting behaviors and the onset of smoking and alcohol use: a longitudinal study. Pediatrics 94, 368–375 (1994).
pubmed: 8065865
Fergusson, D. M., Horwood, L. J. & Lynskey, M. T. Parental separation, adolescent psychopathology, and problem behaviors. J. Am. Acad. Child Adolesc. Psychiatry 33, 1122–1131 (1994).
pubmed: 7982863 doi: 10.1097/00004583-199410000-00008
Conroy, E., Degenhardt, L., Mattick, R. P. & Nelson, E. C. Child maltreatment as a risk factor for opioid dependence: comparison of family characteristics and type and severity of child maltreatment with a matched control group. Child Abuse Negl. 33, 343–352 (2009).
pubmed: 19477004 pmcid: 2729332 doi: 10.1016/j.chiabu.2008.09.009
Needle, R. H., Su, S. & Doherty, W. J. Divorce, remarriage, and adolescent drug involvement: a prospective longitudinal study. J. Marriage Family 52, 157–169 (1990).
doi: 10.2307/352847
Campbell, G. et al. Pharmaceutical opioid use and dependence among people living with chronic pain: associations observed within the pain and opioids in treatment (POINT) cohort. Pain. Med. 16, 1745–1758 (2015).
pubmed: 26011277 doi: 10.1111/pme.12773
Lynskey, M. T. & Fergusson, D. M. Childhood conduct problems and attention deficit behaviors and adolescent alcohol, tobacco and illicit drug use. J. Abnorm. Child Psychol. 23, 281–302 (1995).
pubmed: 7642838 doi: 10.1007/BF01447558
Townsend, L., Flisher, A. & King, G. A systematic review of the relationship between high school dropout and substance use. Clin. Child Family Psychol. Rev. 10, 295–317 (2007).
doi: 10.1007/s10567-007-0023-7
Katz, C., El-Gabalawy, R., Keyes, K. M., Martins, S. S. & Sareen, J. Risk factors for incident nonmedical prescription opioid use and abuse and dependence: results from a longitudinal nationally representative sample. Drug Alcohol Depend. 132, 107–113 (2013).
pubmed: 23399466 pmcid: 5408745 doi: 10.1016/j.drugalcdep.2013.01.010
Sullivan, M. D. Who gets high-dose opioid therapy for chronic non-cancer pain? Pain 151, 567–568 (2010).
pubmed: 20826051 doi: 10.1016/j.pain.2010.08.036
Institute of Medicine & Committee on Opportunities in Drug Abuse Research. Pathways of Addiction: Opportunities in Drug Abuse Research. (National Academy Press, 1996).
Academy Medical Sciences. Brain science, addiction and drugs (ed. Horn, G.) (Academy Medical Sciences, 2007).
Macleod, J. et al. Early life influences on the risk of injecting drug use: case control study based on the edinburgh addiction cohort. Addiction 108, 743–750 (2013).
pubmed: 23163301 doi: 10.1111/add.12056
Butt, S., Chou, S. & Browne, K. A rapid systematic review on the association between childhood physical and sexual abuse and illicit drug use among males. Child Abuse Rev. 20, 6–38 (2011).
doi: 10.1002/car.1100
Konkoly Thege, B. et al. Relationship between interpersonal trauma exposure and addictive behaviors: a systematic review. BMC Psychiatry 17, 164 (2017).
pubmed: 28472931 pmcid: 5418764 doi: 10.1186/s12888-017-1323-1
Darke, S., Torok, M. & Ross, J. Developmental trajectories to heroin dependence: theoretical and clinical issues. J. Appl. Soc. Psychol. 47, 165–171 (2017).
doi: 10.1111/jasp.12434
Darke, S. Pathways to heroin dependence: time to re-appraise self-medication. Addiction 108, 659–667 (2013).
pubmed: 23075121 doi: 10.1111/j.1360-0443.2012.04001.x
Martins, S. S. et al. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the national epidemiologic study on alcohol and related conditions. Psychol. Med. 42, 1261–1272 (2012).
pubmed: 21999943 doi: 10.1017/S0033291711002145
Dasgupta, N., Beletsky, L. & Ciccarone, D. Opioid crisis: no easy fix to its social and economic determinants. Am. J. Public Health 108, 182–186 (2018).
pubmed: 29267060 pmcid: 5846593 doi: 10.2105/AJPH.2017.304187
Degenhardt, L. et al. Evaluating the drug use “gateway” theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the who world mental health surveys. Drug Alcohol Depend. 108, 84–97 (2010).
pubmed: 20060657 pmcid: 2835832 doi: 10.1016/j.drugalcdep.2009.12.001
Rudd, R. A., Aleshire, N., Zibbell, J. E. & Matthew Gladden, R. Increases in drug and opioid overdose deaths — United States, 2000–2014. Am. J. Transplant. 16, 1323–1327 (2016).
doi: 10.1111/ajt.13776
O’Donnell, J., Halpin, J., Mattson, C. L., Goldberger, B. A. & Gladden, R. M. Deaths involving fentanyl, fentanyl analogs, and U-47700 — 10 states, July–December 2016. MMWR Morb. Mortal. Wkly Rep. 66, 1197–1202 (2017).
pubmed: 29095804 pmcid: 5689219 doi: 10.15585/mmwr.mm6643e1
Gladden, R., Martinez, P. & Seth, P. Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths — 27 states, 2013–2014. MMWR Morb. Mortal. Wkly Rep. 65, 837–843 (2016).
pubmed: 27560775 doi: 10.15585/mmwr.mm6533a2
Fischer, B., Russell, C., Murphy, Y. & Kurdyak, P. Prescription opioids, abuse and public health in Canada: is fentanyl the new centre of the opioid crisis? Pharmacoepidemiology Drug Saf. 24, 1334–1336 (2015).
doi: 10.1002/pds.3901
Carroll, J. J., Marshall, B. D. L., Rich, J. D. & Green, T. C. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study. Int. J. Drug Policy 46, 136–145 (2017).
pubmed: 28578864 pmcid: 5560423 doi: 10.1016/j.drugpo.2017.05.023
Somerville, N. J. et al. Characteristics of fentanyl overdose — Massachusetts, 2014–2016. MMWR Morb. Mortal. Wkly Rep. 66, 382–386 (2017).
pubmed: 28406883 pmcid: 5657806 doi: 10.15585/mmwr.mm6614a2
Centers for Disease Control and Prevention. Viral hepatitis surveillance United States, 2015 (CDC, 2016).
Suryaprasad, A. G. et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin. Infect. Dis. 59, 1411–1419 (2014).
pubmed: 25114031 doi: 10.1093/cid/ciu643
Zibbell, J. E. et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years – Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb. Mortal. Wkly Rep. 64, 453–458 (2015).
pubmed: 25950251 pmcid: 4584548
Volkow, N. D. Opioids in pregnancy. BMJ 352, i19 (2016).
pubmed: 26759359 doi: 10.1136/bmj.i19
Larney, S. et al All-cause and cause-specific mortality in people using extra-medical opioids: a systematic review and meta-analysis. JAMA Psychiatry (in the press).
Maloney, E., Degenhardt, L., Darke, S., Mattick, R. P. & Nelson, E. Suicidal behaviour and associated risk factors among opioid-dependent individuals: a case-control study. Addiction 102, 1933–1941 (2007).
pubmed: 17784898 doi: 10.1111/j.1360-0443.2007.01971.x
Degenhardt, L. et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob. Health 5, e1192–e1207 (2017).
pubmed: 29074409 pmcid: 5683738 doi: 10.1016/S2214-109X(17)30375-3
Degenhardt, L. et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the global burden of disease study 2013. Lancet Infect. Dis. 16, 1385–1398 (2016).
pubmed: 27665254 doi: 10.1016/S1473-3099(16)30325-5
Larney, S., Peacock, A., Mathers, B. M., Hickman, M. & Degenhardt, L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 171, 39–49 (2017).
pubmed: 28013096 doi: 10.1016/j.drugalcdep.2016.11.029
Goldstein, R. Z. & Volkow, N. D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry 159, 1642–1652 (2002).
pubmed: 12359667 pmcid: 12359667 doi: 10.1176/appi.ajp.159.10.1642
Koob, G. F. & Le Moal, M. Drug abuse: hedonic homeostatic dysregulation. Science 278, 52–58 (1997).
pubmed: 9311926 doi: 10.1126/science.278.5335.52
Mansour, A., Fox, C. A., Akil, H. & Watson, S. J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18, 22–29 (1995).
pubmed: 7535487 doi: 10.1016/0166-2236(95)93946-U
Lutz, P. E. & Kieffer, B. L. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 36, 195–206 (2013).
pubmed: 23219016 doi: 10.1016/j.tins.2012.11.002
O’Briend, C. P. “Needle freaks”: Psychological Dependence on Shooting Up. in Medical World News, Psychiatry Annual (McGraw Hill, 1974).
Meyer, R. E., & Mirin, S. M. The Heroin Stimulus: Implications for a Theory of Addiction (Springer, 1979).
Chen, S. A. et al. Unlimited access to heroin self-administration: independent motivational markers of opiate dependence. Neuropsychopharmacology 31, 2692–2707 (2006).
pubmed: 16452993 doi: 10.1038/sj.npp.1301008
Mucha, R. F., van der Kooy, D., O’Shaughnessy, M. & Bucenieks, P. Drug reinforcement studied by the use of place conditioning in rat. Brain Res. 243, 91–105 (1982).
pubmed: 6288174 doi: 10.1016/0006-8993(82)91123-4
Le Merrer, J., Becker, J. A., Befort, K. & Kieffer, B. L. Reward processing by the opioid system in the brain. Physiol. Rev. 89, 1379–1412 (2009).
pubmed: 19789384 pmcid: 4482114 doi: 10.1152/physrev.00005.2009
Guignard, B. et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 93, 409–417 (2000).
pubmed: 10910490 doi: 10.1097/00000542-200008000-00019
Laulin, J. P., Celerier, E., Larcher, A., Le Moal, M. & Simonnet, G. Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience 89, 631–636 (1999).
pubmed: 10199599 doi: 10.1016/S0306-4522(98)00652-6
Martin, W. R. et al. Methadone – a reevaluation. Arch. Gen. Psychiatry 28, 286–295 (1973).
pubmed: 4684295 doi: 10.1001/archpsyc.1973.01750320112017
Yaksh, T. & Wallace, M. in Goodman and Gilman’s Pharmacological Basis of Therapeutics Ch. 20 (McGraw-Hill Education, 2017).
Cahill, C. M. et al. Does the κ opioid receptor system contribute to pain aversion? Front. Pharmacol. 5, 253 (2014).
pubmed: 25452729 pmcid: 4233910 doi: 10.3389/fphar.2014.00253
Gaspari, S. et al. Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine. Neuropsychopharmacology 39, 1968–1977 (2014).
pubmed: 24561386 pmcid: 4059906 doi: 10.1038/npp.2014.45
Fields, H. State-dependent opioid control of pain. Nat. Rev. Neurosci. 5, 565–575 (2004).
pubmed: 15208698 doi: 10.1038/nrn1431
Raehal, K. M. & Bohn, L. M. β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb. Exp. Pharmacol. 219, 427–443 (2014).
pubmed: 24292843 pmcid: 4804701 doi: 10.1007/978-3-642-41199-1_22
Bohn, L. M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J. & Caron, M. G. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408, 720–723 (2000).
pubmed: 11130073 doi: 10.1038/35047086
Schmid, C. L. et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell 171, 1165–1175 (2017).
pubmed: 29149605 pmcid: 5731250 doi: 10.1016/j.cell.2017.10.035
Volkow, N. D. & McLellan, A. T. Opioid abuse in chronic pain-misconceptions and mitigation strategies. N. Engl. J. Med. 374, 1253–1263 (2016). This paper reviews the pharmacological properties of opoids that underlie their analgesic and rewarding effects, and identifies the cellular and neurobiological processes that result in physical dependence and tolerance versus those responsibe for addiction in the context of their implications vis a vis treatment.
pubmed: 27028915 doi: 10.1056/NEJMra1507771
Latowsky, M. Improving detoxification outcomes from methadone maintenance treatment: the interrelationship of affective states and protracted withdrawal. J. Psychoact. Drugs 28, 251–257 (1996).
doi: 10.1080/02791072.1996.10472486
O’Brien, C. P., Testa, T., O’Brien, T. J., Brady, J. P. & Wells, B. Conditioned narcotic withdrawal in humans. Science 195, 1000–1002 (1977).
pubmed: 841320 doi: 10.1126/science.841320
Heimer, L. & Alheid, G. F. Piecing together the puzzle of basal forebrain anatomy. Adv. Exp. Med. Biol. 295, 1–42 (1991).
pubmed: 1776564 doi: 10.1007/978-1-4757-0145-6_1
Koob, G. F. The dark side of emotion: the addiction perspective. Eur. J. Pharmacol. 753, 73–87 (2015).
pubmed: 25583178 pmcid: 4380644 doi: 10.1016/j.ejphar.2014.11.044
Pothos, E., Rada, P., Mark, G. P. & Hoebel, B. G. Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res. 566, 348–350 (1991).
pubmed: 1814554 doi: 10.1016/0006-8993(91)91724-F
Rossetti, Z. L., Hmaidan, Y. & Gessa, G. L. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur. J. Pharmacol. 221, 227–234 (1992).
pubmed: 1426002 doi: 10.1016/0014-2999(92)90706-A
Wang, G. J. et al. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16, 174–182 (1997).
pubmed: 9015800 doi: 10.1016/S0893-133X(96)00184-4
Zijlstra, F., Veltman, D. J., Booij, J., van den Brink, W. & Franken, I. H. Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. Drug Alcohol Depend. 99, 183–192 (2009).
pubmed: 18823721 doi: 10.1016/j.drugalcdep.2008.07.012
Koob, G. F. & Bloom, F. E. Cellular and molecular mechanisms of drug dependence. Science 242, 715–723 (1988).
pubmed: 2903550 doi: 10.1126/science.2903550
Greenwell, T. N. et al. Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats. Addict. Biol. 14, 130–143 (2009).
pubmed: 19291009 pmcid: 2748834 doi: 10.1111/j.1369-1600.2008.00142.x
Greenwell, T. N., Walker, B. M., Cottone, P., Zorrilla, E. P. & Koob, G. F. The α1 adrenergic receptor antagonist prazosin reduces heroin self-administration in rats with extended access to heroin administration. Pharmacol. Biochem. Behav. 91, 295–302 (2009).
pubmed: 18703080 doi: 10.1016/j.pbb.2008.07.012
Park, P. E. et al. Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia. Addict. Biol. 20, 275–284 (2015).
pubmed: 24330252 doi: 10.1111/adb.12120
Whitfield, T. W. Jr et al. κ opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake. J. Neurosci. 35, 4296–4305 (2015).
pubmed: 25762676 pmcid: 4355200 doi: 10.1523/JNEUROSCI.1978-13.2015
Chavkin, C. & Koob, G. F. Dynorphin, dysphoria, and dependence: the stress of addiction. Neuropsychopharmacology 41, 373–374 (2016).
pubmed: 26657953 doi: 10.1038/npp.2015.258
Carlezon, W. A. Jr., Nestler, E. J. & Neve, R. L. Herpes simplex virus-mediated gene transfer as a tool for neuropsychiatric research. Crit. Rev. Neurobiol. 14, 47–67 (2000).
pubmed: 11253955 doi: 10.1615/CritRevNeurobiol.v14.i1.30
Volkow, N. D., Hampson, A. J. & Baler, R. D. Don’t worry, be happy: endocannabinoids and cannabis at the intersection of stress and reward. Annu. Rev. Pharmacol. Toxicol. 57, 285–308 (2017).
pubmed: 27618739 doi: 10.1146/annurev-pharmtox-010716-104615
Volkow, N. D. et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14, 169–177 (1993).
pubmed: 8101394 doi: 10.1002/syn.890140210
Pirastu, R. et al. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend. 83, 163–168 (2006).
pubmed: 16343811 doi: 10.1016/j.drugalcdep.2005.11.008
Stewart, J. & Wise, R. A. Reinstatement of heroin self-administration habits: morphine prompts and naltrexone discourages renewed responding after extinction. Psychopharmacology 108, 79–84 (1992).
pubmed: 1410149 doi: 10.1007/BF02245289
Kalivas, P. W. The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 10, 561–572 (2009).
pubmed: 19571793 doi: 10.1038/nrn2515
Bossert, J. M. et al. Role of projections from ventral subiculum to nucleus accumbens shell in context-induced reinstatement of heroin seeking in rats. Psychopharmacology 233, 1991–2004 (2016).
pubmed: 26344108 doi: 10.1007/s00213-015-4060-5
Bossert, J. M., Busch, R. F. & Gray, S. M. The novel mGluR2/3 agonist LY379268 attenuates cue-induced reinstatement of heroin seeking. Neuroreport 16, 1013–1016 (2005).
pubmed: 15931079 doi: 10.1097/00001756-200506210-00026
Shaham, Y., Erb, S. & Stewart, J. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res. Rev. 33, 13–33 (2000).
pubmed: 10967352 doi: 10.1016/S0165-0173(00)00024-2
Kreek, M. J. Opiates, opioids and addiction. Mol. Psychiatry 1, 232–254 (1996).
pubmed: 9118348
Kreek, M. J. Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. Neurochem. Res. 21, 1469–1488 (1996).
pubmed: 8947936 doi: 10.1007/BF02532387
Stinus, L., Caille, S. & Koob, G. F. Opiate withdrawal-induced place aversion lasts for up to 16 weeks. Psychopharmacology 149, 115–120 (2000).
pubmed: 10805605 doi: 10.1007/s002139900358
Gracy, K. N., Dankiewicz, L. A. & Koob, G. F. Opiate withdrawal-induced fos immunoreactivity in the rat extended amygdala parallels the development of conditioned place aversion. Neuropsychopharmacology 24, 152–160 (2001).
pubmed: 11120397 doi: 10.1016/S0893-133X(00)00186-X
Kenny, P. J., Chen, S. A., Kitamura, O., Markou, A. & Koob, G. F. Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J. Neurosci. 26, 5894–5900 (2006).
pubmed: 16738231 pmcid: 6675212 doi: 10.1523/JNEUROSCI.0740-06.2006
Epstein, D. H. et al. Real-time electronic diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use. Arch. Gen. Psychiatry 66, 88–94 (2009).
pubmed: 19124692 pmcid: 2943840 doi: 10.1001/archgenpsychiatry.2008.509
Chase, H. W., Eickhoff, S. B., Laird, A. R. & Hogarth, L. The neural basis of drug stimulus processing and craving: an activation likelihood estimation meta-analysis. Biol. Psychiatry 70, 785–793 (2011).
pubmed: 21757184 pmcid: 4827617 doi: 10.1016/j.biopsych.2011.05.025
Kuhn, S. & Gallinat, J. Common biology of craving across legal and illegal drugs - a quantitative meta-analysis of cue-reactivity brain response. Eur. J. Neurosci. 33, 1318–1326 (2011).
pubmed: 21261758 doi: 10.1111/j.1460-9568.2010.07590.x
Nestler, E. J. Under siege: the brain on opiates. Neuron 16, 897–900 (1996).
pubmed: 8630245 doi: 10.1016/S0896-6273(00)80110-5
Collier, H. O. & Francis, D. L. Morphine abstinence is associated with increased brain cyclic AMP. Nature 255, 159–162 (1975).
pubmed: 165429 doi: 10.1038/255159b0
Nestler, E. J. & Malenka, R. C. The addicted brain. Sci. Am. 290, 78–85 (2004). This paper provides an overview of the molecular mechanims responsible for the neuroplastic adaptations at the cellular and synaptic level and how there contribute to the long-lasting changes in behaviour from repeated drug use.
pubmed: 14981881 doi: 10.1038/scientificamerican0304-78
Goldman, D., Oroszi, G. & Ducci, F. The genetics of addictions: uncovering the genes. Nat. Rev. Genet. 6, 521–532 (2005).
pubmed: 15995696 doi: 10.1038/nrg1635
Levran, O., Yuferov, V. & Kreek, M. J. The genetics of the opioid system and specific drug addictions. Hum. Genet. 131, 823–842 (2012).
pubmed: 22547174 pmcid: 3721349 doi: 10.1007/s00439-012-1172-4
Yiannakopoulou, E. Pharmacogenomics and opioid analgesics: clinical implications. Int. J. Genomics 2015, 368979 (2015).
pubmed: 26075211 pmcid: 4446490 doi: 10.1155/2015/368979
Hancock, D. B. et al. Cis-expression quantitative trait loci mapping reveals replicable associations with heroin addiction in OPRM1. Biol. Psychiatry 78, 474–484 (2015).
pubmed: 25744370 pmcid: 4519434 doi: 10.1016/j.biopsych.2015.01.003
Nielsen, L. M. et al. Association between human pain-related genotypes and variability in opioid analgesia: an updated review. Pain Pract. 15, 580–594 (2015).
pubmed: 25201705 doi: 10.1111/papr.12232
Jensen, K. P. A review of genome-wide association studies of stimulant and opioid use disorders. Mol. Neuropsychiatry 2, 37–45 (2016).
pubmed: 27606319 pmcid: 4996024 doi: 10.1159/000444755
Gelernter, J. et al. Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol. Psychiatry 76, 66–74 (2014).
pubmed: 24143882 doi: 10.1016/j.biopsych.2013.08.034
Nelson, E. C. et al. Evidence of CNIH3 involvement in opioid dependence. Mol. Psychiatry 21, 608–614 (2016).
pubmed: 26239289 doi: 10.1038/mp.2015.102
Lee, C. W. & Ho, I. K. Sex differences in opioid analgesia and addiction: interactions among opioid receptors and estrogen receptors. Mol. Pain 9, 45 (2013).
pubmed: 24010861 pmcid: 3844594 doi: 10.1186/1744-8069-9-45
US Department of Health and Human Services. Substance abuse and mental health data archive (SAMHSA, 2018).
Brady, K. T. & Randall, C. L. Gender differences in substance use disorders. Psychiatr. Clin. North Am. 22, 241–252 (1999).
pubmed: 10385931 doi: 10.1016/S0193-953X(05)70074-5
Chartoff, E. H. & Mavrikaki, M. Sex differences in kappa opioid receptor function and their potential impact on addiction. Front. Neurosci. 9, 466 (2015).
pubmed: 26733781 pmcid: 4679873 doi: 10.3389/fnins.2015.00466
Wiesenfeld-Hallin, Z. Sex differences in pain perception. Gend. Med. 2, 137–145 (2005).
pubmed: 16290886 doi: 10.1016/S1550-8579(05)80042-7
Zubieta, J. K., Dannals, R. F. & Frost, J. J. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am. J. Psychiatry 156, 842–848 (1999).
pubmed: 10360121 doi: 10.1176/ajp.156.6.842
Zubieta, J. K. et al. µ-opioid receptor-mediated antinociceptive responses differ in men and women. J. Neurosci. 22, 5100–5107 (2002).
pubmed: 12077205 pmcid: 6757760 doi: 10.1523/JNEUROSCI.22-12-05100.2002
Vijay, A. et al. PET imaging reveals sex differences in κ opioid receptor availability in humans, in vivo. Am. J. Nucl. Med. Mol. Imaging 6, 205–214 (2016).
pubmed: 27648372 pmcid: 5004062
Simonnet, G. & Rivat, C. Opioid-induced hyperalgesia: abnormal or normal pain? Neuroreport 14, 1–7 (2003).
pubmed: 12544821 doi: 10.1097/00001756-200301200-00001
Compton, P., Athanasos, P. & Elashoff, D. Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J. Pain 4, 511–519 (2003).
pubmed: 14636819 doi: 10.1016/j.jpain.2003.08.003
Doverty, M. et al. Hyperalgesic responses in methadone maintenance patients. Pain 90, 91–96 (2001).
pubmed: 11166974 doi: 10.1016/S0304-3959(00)00391-2
Tsui, J. I. et al. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy. Drug Alcohol Depend. 166, 26–31 (2016).
pubmed: 27422763 pmcid: 4983520 doi: 10.1016/j.drugalcdep.2016.06.024
Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C. V. & Hurd, Y. L. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J. Neurosci. 29, 14764–14769 (2009).
pubmed: 19940171 pmcid: 2829756 doi: 10.1523/JNEUROSCI.4291-09.2009
Carcoba, L. M., Contreras, A. E., Cepeda-Benito, A. & Meagher, M. W. Negative affect heightens opiate withdrawal-induced hyperalgesia in heroin dependent individuals. J. Addict. Dis. 30, 258–270 (2011).
pubmed: 21745048 pmcid: 3209757 doi: 10.1080/10550887.2011.581985
Laulin, J. P., Larcher, A., Celerier, E., Le Moal, M. & Simonnet, G. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur. J. Neurosci. 10, 782–785 (1998).
pubmed: 9749743 doi: 10.1046/j.1460-9568.1998.00083.x
Fu, Y. & Neugebauer, V. Differential mechanisms of CRF1 and CRF2 receptor functions in the amygdala in pain-related synaptic facilitation and behavior. J. Neurosci. 28, 3861–3876 (2008).
pubmed: 18400885 pmcid: 2557030 doi: 10.1523/JNEUROSCI.0227-08.2008
Koob, G. F. & Volkow, N. D. Neurocircuitry of addiction. Neuropsychopharmacology 35, 217–238 (2010). This paper provides a model that integrates neuroscientific advances from preclinical studies and from neuroimaging studies in individuals who are addicted, and identifies the main neurocircuits and neurotransmitters implicated in the three phases of the addiction cycle.
pubmed: 19710631 doi: 10.1038/npp.2009.110
Koob, G. F. & Le Moal, M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24, 97–129 (2001).
pubmed: 11120394 doi: 10.1016/S0893-133X(00)00195-0
Shurman, J., Koob, G. F. & Gutstein, H. B. Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med. 11, 1092–1098 (2010).
pubmed: 20545871 pmcid: 2907890 doi: 10.1111/j.1526-4637.2010.00881.x
Neugebauer, V. The amygdala: different pains, different mechanisms. Pain 127, 1–2 (2007).
pubmed: 17118556 doi: 10.1016/j.pain.2006.10.004
Price, D. D. Psychological and neural mechanisms of the affective dimension of pain. Science 288, 1769–1772 (2000).
pubmed: 10846154 doi: 10.1126/science.288.5472.1769
Bester, H., Menendez, L., Besson, J. M. & Bernard, J. F. Spino (trigemino) parabrachiohypothalamic pathway: electrophysiological evidence for an involvement in pain processes. J. Neurophysiol. 73, 568–585 (1995).
pubmed: 7760119 doi: 10.1152/jn.1995.73.2.568
McNally, G. P. & Akil, H. Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal. Neuroscience 112, 605–617 (2002).
pubmed: 12074902 doi: 10.1016/S0306-4522(02)00105-7
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 5th edn (APA, 2013).
Nelson, H. D., Matthews, A. M., Girard, D. E. & Bloom, J. D. Substance-impaired physicians probationary and voluntary treatment programs compared. West. J. Med. 165, 31–36 (1996).
pubmed: 8855682 pmcid: 1307538
White, J. M. & Irvine, R. J. Mechanisms of fatal opioid overdose. Addiction 94, 961–972 (1999).
pubmed: 10707430 doi: 10.1046/j.1360-0443.1999.9479612.x
Pierce, M., Bird, S. M., Hickman, M. & Millar, T. National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005–2009. Drug Alcohol Depend. 146, 17–23 (2015).
pubmed: 25454405 pmcid: 4294586 doi: 10.1016/j.drugalcdep.2014.09.782
Gibson, A., Randall, D. & Degenhardt, L. The increasing mortality burden of liver disease among opioid-dependent people: cohort study. Addiction 106, 2186–2192 (2011).
pubmed: 21749525 doi: 10.1111/j.1360-0443.2011.03575.x
Csete, J. et al. Public health and international drug policy. Lancet 387, 1427–1480 (2016).
pubmed: 27021149 pmcid: 5042332 doi: 10.1016/S0140-6736(16)00619-X
Drucker, E. Population impact of mass incarceration under New York’s rockefeller drug laws: an analysis of years of life lost. J. Urban Health 79, 434–435 (2002).
pubmed: 12200514 pmcid: 3456796 doi: 10.1093/jurban/79.3.434
Faggiano, F., Minozzi, S., Versino, E. & Buscemi, D. Universal school-based prevention for illicit drug use. Cochrane Database Syst. Rev. 12, CD003020 (2014).
Foxcroft, D. R. & Tsertsvadze, A. Universal alcohol misuse prevention programmes for children and adolescents: cochrane systematic reviews. Perspect. Public Health 132, 128–134 (2012).
pubmed: 22700577 doi: 10.1177/1757913912443487
Stockings, E. et al. Prevention, early intervention, harm reduction, and treatment of substance use in young people. Lancet Psychiatry https://doi.org/10.1016/S2215-0366(16)00002-X (2016).
doi: 10.1016/S2215-0366(16)00002-X pubmed: 26905482
Georgie, J. M., Sean, H., Deborah, M. C., Matthew, H. & Rona, C. Peer-led interventions to prevent tobacco, alcohol and/or drug use among young people aged 11-21 years: a systematic review and meta-analysis. Addiction 111, 391–407 (2016).
doi: 10.1111/add.13224
Reuter, P. & Kleiman, M. A. R. Risks and prices: an economic analysis of drug enforcement. Crime Justice 7, 289–340 (1986).
doi: 10.1086/449116
Jalal, H. et al. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science 361, eaau1184 (2018).
pubmed: 30237320 doi: 10.1126/science.aau1184
Day, C., Degenhardt, L. & Hall, W. Documenting the heroin shortage in New South Wales. Drug. Alcohol. Rev. 25, 297–305 (2006).
pubmed: 16854654 doi: 10.1080/09595230600741024
Day, C., Degenhardt, L. & Hall, W. Changes in the initiation of heroin use after a reduction in heroin supply. Drug. Alcohol. Rev. 25, 307–313 (2006).
pubmed: 16854655 doi: 10.1080/09595230600741040
Luchenski, S. et al. What works in inclusion health: overview of effective interventions for marginalised and excluded populations. Lancet 391, 266–280 (2018).
pubmed: 29137868 doi: 10.1016/S0140-6736(17)31959-1
Berterame, S. et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet 87, 1644–1656 (2016).
doi: 10.1016/S0140-6736(16)00161-6
Ballantyne, J. C. & Mao, J. Opioid therapy for chronic pain. N. Engl. J. Med. 349, 1943–1953 (2003).
pubmed: 14614170 doi: 10.1056/NEJMra025411
Krawczyk, N. et al. Predictors of overdose death among high-risk emergency department patients with substance-related encounters: a data linkage cohort study. Ann. Emerg. Med. https://doi.org/10.1016/j.annemergmed.2019.07.014 (2019).
doi: 10.1016/j.annemergmed.2019.07.014 pubmed: 31515181 pmcid: 6928412
Haffajee, R. L., Lin, L. A., Bohnert, A. S. B. & Goldstick, J. E. Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Netw. Open 2, e196373 (2019).
pubmed: 31251376 pmcid: 6604101 doi: 10.1001/jamanetworkopen.2019.6373
British Pain Society. Guidelines for pain management programmes for adults (British Pain Society, 2013).
Centers for Disease Control and Prevention. Guideline for prescribing opioids for chronic pain (CDC, 2016).
Busse, J. W. et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ 189, E659–E666 (2017).
pubmed: 28483845 pmcid: 5422149 doi: 10.1503/cmaj.170363
Al Achkar, M. et al. The effects of state rules on opioid prescribing in Indiana. BMC Health Serv. Res. 18, 29 (2018).
pubmed: 29347984 pmcid: 5774127 doi: 10.1186/s12913-018-2830-6
Moyo, P. et al. Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among medicare beneficiaries in 10 US States. Addiction 112, 1784–1796 (2017).
pubmed: 28498498 doi: 10.1111/add.13860
Rhodes, E., Wilson, M., Robinson, A., Hayden, J. A. & Asbridge, M. The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review. BMC Health Serv. Res. 19, 784 (2019).
pubmed: 31675963 pmcid: 6825333 doi: 10.1186/s12913-019-4642-8
Haegerich, T. M., Jones, C. M., Cote, P. O., Robinson, A. & Ross, L. Evidence for state, community and systems-level prevention strategies to address the opioid crisis. Drug Alcohol Depend 204, 107563 (2019).
pubmed: 31585357 doi: 10.1016/j.drugalcdep.2019.107563
Lin, L. A. et al. Impact of the opioid safety initiative on opioid-related prescribing in veterans. Pain 158, 833–839 (2017).
pubmed: 28240996 doi: 10.1097/j.pain.0000000000000837
Irvine, M. A. et al. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. Addiction 114, 1602–1613 (2019).
pubmed: 31166621 doi: 10.1111/add.14664
Barnett, M. L., Gray, J., Zink, A. & Jena, A. B. Coupling policymaking with evaluation - the case of the opioid crisis. N. Engl. J. Med. 377, 2306–2309 (2017).
pubmed: 29236636 doi: 10.1056/NEJMp1710014
Kariisa, M., Scholl, L., Wilson, N., Seth, P. & Hoots, B. Drug overdose deaths involving cocaine and psychostimulants with abuse potential - united states, 2003-2017. MMWR Morb. Mortal. Wkly. Rep. 68, 388–395 (2019).
pubmed: 31048676 pmcid: 6541315 doi: 10.15585/mmwr.mm6817a3
Kertesz, S. G. Turning the tide or riptide? The changing opioid epidemic. Subst. Abus. 38, 3–8 (2017).
pubmed: 27858590 doi: 10.1080/08897077.2016.1261070
Compton, W. M., Jones, C. M. & Baldwin, G. T. Relationship between nonmedical prescription-opioid use and heroin use. N. Engl. J. Med. 374, 154–163 (2016).
pubmed: 26760086 doi: 10.1056/NEJMra1508490
European Monitoring Centre for Drugs and Drug Addiction. Harm reduction: evidence, impacts and challenges (EMCDDA, 2010).
World Health Organization. Harm reduction (WHO, 2019).
European Centre for Disease Prevention and Control & European Monitoring Centre for Drugs and Drug Addiction. Prevention and control of infectious diseases among people who inject drugs (EMCDDA, 2011).
Amato, L. et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J. Subst. Abuse Treat. 28, 321–329 (2005). This review paper examines evidence from a set of five Cochrane reviews of different aspects of MOUD, comparing OAT with no treatment and with detoxification as well as with OAT utilizing different available medications, and integrates the evidence in a way that is designed to guide both clinical practice and associated research.
pubmed: 15925266 doi: 10.1016/j.jsat.2005.02.007
Mattick, R. P., Breen, C., Kimber, J. & Davoli, M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev 8, CD002209 (2009).
Mathers, B. M. et al. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull. World Health Organ. 91, 102–123 (2013).
pubmed: 23554523 pmcid: 3605003 doi: 10.2471/BLT.12.108282
MacArthur, G. J., Jacob, N., Pound, P., Hickman, M. & Campbell, R. Among friends: a qualitative exploration of the role of peers in young people’s alcohol use using Bourdieu’s concepts of habitus, field and capital. Sociol. Health Illn. 39, 30–46 (2017).
pubmed: 27573161 doi: 10.1111/1467-9566.12467
MacArthur, G. J. et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 345, e5945 (2012).
pubmed: 23038795 pmcid: 3489107 doi: 10.1136/bmj.e5945
Platt, L. et al. Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction 113, 545–563 (2018). This review paper draws on a Cochrane review of needle exchange and conducts metaanalysis to identify the extent to which both needle exchange and OAT protect against transmission of HCV infection: this review considers each of OAT and needle and syringe programmes separately, and also in combination.
pubmed: 28891267 doi: 10.1111/add.14012
Platt, L. et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst. Rev. 9, CD012021 (2017).
pubmed: 28922449
Godfrey, C., Stewart, D. & Gossop, M. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the national treatment outcome research study (NTORS). Addiction 99, 697–707 (2004).
pubmed: 15139868 doi: 10.1111/j.1360-0443.2004.00752.x
Low, A. J. et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin. Infect. Dis. 63, 1094–1104 (2016).
pubmed: 27343545 pmcid: 5036913 doi: 10.1093/cid/ciw416
Connock, M. et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol. Assess. 11, 1–171 (2007).
pubmed: 17313907
Gisev, N. et al. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. Addiction 110, 1975–1984 (2015).
pubmed: 26212260 doi: 10.1111/add.13073
Martin, N. K., Miners, A. & Vickerman, P. Assessing the cost-effectiveness of interventions aimed at promoting and offering hepatitis C testing to injecting drug users: an economic modelling report (NICE, 2012).
McLellan, A. T., Lewis, D. C., O’Brien, C. P. & Kleber, H. D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284, 1689–1695 (2000).
pubmed: 11015800 doi: 10.1001/jama.284.13.1689
O’Brien, C. P. & McLellan, A. T. Myths about the treatment of addiction. Lancet 347, 237–240 (1996).
pubmed: 8551886 doi: 10.1016/S0140-6736(96)90409-2
Marsden, J. et al. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction 112, 1408–1418 (2017). This large-scale observational study compares provision of OAT (versus non-provision) to prisoners during and after imprisonment: the study starts from the point of prior awareness of the considerable excess mortality of drug-using former prisoners during the first few weeks post-release, confirms this particular excess mortality in the first month, and also identifies the substantial protective effect of OAT.
pubmed: 28160345 doi: 10.1111/add.13779
Degenhardt, L. et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction 109, 1306–1017 (2014).
pubmed: 24612249 doi: 10.1111/add.12536
Fazel, S., Bains, P. & Doll, H. Substance abuse and dependence in prisoners: a systematic review. Addiction 101, 181–191 (2006).
pubmed: 16445547 doi: 10.1111/j.1360-0443.2006.01316.x
Rich, J. D. et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet 386, 350–359 (2015).
pubmed: 26028120 pmcid: 4522212 doi: 10.1016/S0140-6736(14)62338-2
Larney, S. et al. Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. BMJ Open. 4, e004666 (2014).
pubmed: 24694626 pmcid: 3987723 doi: 10.1136/bmjopen-2013-004666
Taylor, A. et al. Low incidence of hepatitis C virus amongst prisoners in Scotland. Addiction 108, 1296–1304 (2013).
pubmed: 23297816 doi: 10.1111/add.12107
Stone, J. et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction 112, 1302–1314 (2017).
pubmed: 28257600 pmcid: 5461206 doi: 10.1111/add.13783
Fraser, H. et al. Scaling up HCV prevention and treatment interventions in rural USA - model projections for tackling an increasing epidemic. Addiction 113, 173–182 (2018).
pubmed: 28734093 doi: 10.1111/add.13948
Cepeda, J. A. et al. Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV 5, e578–e587 (2018).
pubmed: 30033374 pmcid: 6188805 doi: 10.1016/S2352-3018(18)30168-1
Cornish, R., Macleod, J., Strang, J., Vickerman, P. & Hickman, M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK general practice research database. BMJ 341, c5475 (2010).
pubmed: 20978062 pmcid: 2965139 doi: 10.1136/bmj.c5475
Hickman, M. et al. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. Addiction 113, 1461–1476 (2018).
pubmed: 29672985 pmcid: 6282737 doi: 10.1111/add.14188
Martin, N. K. et al. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J. Hepatol. 65, 17–25 (2016).
pubmed: 26867489 pmcid: 4914770 doi: 10.1016/j.jhep.2016.02.007
Aspinall, E. J. et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int. J. Epidemiol. 43, 235–248 (2014).
pubmed: 24374889 doi: 10.1093/ije/dyt243
Strang, J. et al. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction 94, 199–204 (1999).
pubmed: 10396785 doi: 10.1046/j.1360-0443.1999.9421993.x
Strang, J. et al. Family carers and the prevention of heroin overdose deaths: unmet training need and overlooked intervention opportunity of resuscitation training and supply of naloxone. Drugs Educ. Prevent. Policy 15, 211–218 (2008).
doi: 10.1080/09687630701731205
McDonald, R., Campbell, N. D. & Strang, J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-conception and maturation. Drug Alcohol Depend. https://doi.org/10.1016/j.drugalcdep.2017.05.001 (2017).
doi: 10.1016/j.drugalcdep.2017.05.001 pubmed: 28654870
McDonald, R. & Strang, J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 111, 1177–1187 (2016).
pubmed: 27028542 pmcid: 5071734 doi: 10.1111/add.13326
Irvine, M. A. et al. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study. Lancet Public Health 3, e218–e225 (2018).
Potier, C., Laprevote, V., Dubois-Arber, F., Cottencin, O. & Rolland, B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 145, 48–68 (2014).
pubmed: 25456324 doi: 10.1016/j.drugalcdep.2014.10.012
Milloy, M. J., Kerr, T., Tyndall, M., Montaner, J. & Wood, E. Estimated drug overdose deaths averted by North America’s first medically-supervised safer injection facility. PLOS ONE 3, e3351 (2008).
pubmed: 18839040 pmcid: 2556397 doi: 10.1371/journal.pone.0003351
Petrar, S. et al. Injection drug users’ perceptions regarding use of a medically supervised safer injecting facility. Addict. Behav. 32, 1088–1093 (2007).
pubmed: 16930849 doi: 10.1016/j.addbeh.2006.07.013
Wood, E., Tyndall, M. W., Montaner, J. S. & Kerr, T. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ 175, 1399–1404 (2006).
pubmed: 17116909 pmcid: 1635777 doi: 10.1503/cmaj.060863
Global Commission on Drug Policy. globalcommissionondrugs http://www.globalcommissionondrugs.org/ (2019).
Hughes, C. E. & Stevens, A. What can we learn from the Portuguese decriminalization of illicit drugs? Br. J. Criminol. 50, 999-1022 (2010).
doi: 10.1093/bjc/azq038
Felix, S. & Portugal, P. Drug decriminalization and the price of illicit drugs. Int. J. Drug Policy 39, 121–129 (2017).
pubmed: 27940068 doi: 10.1016/j.drugpo.2016.10.014
Goncalves, R., Lourenco, A. & Silva, S. N. A social cost perspective in the wake of the Portuguese strategy for the fight against drugs. Int. J. Drug Policy 26, 199–209 (2015).
pubmed: 25265899 doi: 10.1016/j.drugpo.2014.08.017
National Institute of Drug Abuse. Principles of drug addiction treatment: a research-based guide (NIDA, 2018).
Rich, K. M., Bia, J., Altice, F. L. & Feinberg, J. Integrated models of care for individuals with opioid use disorder: how do we prevent HIV and HCV? Curr. HIV/AIDS Rep. 15, 266–275 (2018).
pubmed: 29774442 pmcid: 6003996 doi: 10.1007/s11904-018-0396-x
Nguyen Bich, D., Korthuis, P. T., Nguyen Thu, T., Van Dinh, H. & Le Minh, G. HIV patients’ preference for integrated models of addiction and HIV treatment in Vietnam. J. Subst. Abuse Treat. 69, 57–63 (2016).
pubmed: 27568511 doi: 10.1016/j.jsat.2016.07.003
Brooner, R. K., King, V. L., Kidorf, M., Schmidt, C. W. Jr & Bigelow, G. E. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch. Gen. Psychiatry 54, 71–80 (1997).
pubmed: 9006403 doi: 10.1001/archpsyc.1997.01830130077015
Petry, N. M., Stinson, F. S. & Grant, B. F. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the national epidemiologic survey on alcohol and related conditions. J. Clin. Psychiatry 66, 564–574 (2005).
pubmed: 15889941 doi: 10.4088/JCP.v66n0504
Meier, A. et al. Co-occurring prescription opioid use problems and posttraumatic stress disorder symptom severity. Am. J. Drug Alcohol Abuse 40, 304–311 (2014).
pubmed: 24809229 pmcid: 4883674 doi: 10.3109/00952990.2014.910519
Conway, K. P., Compton, W., Stinson, F. S. & Grant, B. F. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the national epidemiologic survey on alcohol and related conditions. J. Clin. Psychiatry 67, 247–257 (2006).
pubmed: 16566620 doi: 10.4088/JCP.v67n0211
Fiellin, D. A. et al. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern. Med. 174, 1947–1954 (2014).
pubmed: 25330017 pmcid: 6167926 doi: 10.1001/jamainternmed.2014.5302
Kakko, J., Svanborg, K. D., Kreek, M. J. & Heilig, M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 361, 662–668 (2003).
pubmed: 12606177 doi: 10.1016/S0140-6736(03)12600-1
Newman, R. G. & Whitehill, W. B. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 2, 485–488 (1979).
pubmed: 90214 doi: 10.1016/S0140-6736(79)91550-2
Seaman, S. R., Brettle, R. P. & Gore, S. M. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ 316, 426–428 (1998).
pubmed: 9492665 pmcid: 2665604 doi: 10.1136/bmj.316.7129.426
Farrell, M. & Marsden, J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction 103, 251–255 (2008).
pubmed: 18199304 doi: 10.1111/j.1360-0443.2007.02081.x
Merrall, E. L., Bird, S. M. & Hutchinson, S. J. A record-linkage study of drug-related death and suicide after hospital discharge among drug-treatment clients in Scotland, 1996-2006. Addiction 108, 377–384 (2013).
pubmed: 22925008 doi: 10.1111/j.1360-0443.2012.04066.x
Amato, L., Minozzi, S., Davoli, M. & Vecchi, S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst. Rev. 9, CD005031 (2011).
Gossop, M. The development of a short opiate withdrawal scale (SOWS). Addictive Behav. 15, 487–490 (1990).
doi: 10.1016/0306-4603(90)90036-W
Wesson, D. R. & Ling, W. The clinical opiate withdrawal scale (COWS). J. Psychoact. Drugs 35, 253–259 (2003).
doi: 10.1080/02791072.2003.10400007
Himmelsbach, C. K. The morphine abstinence syndrome, its nature and treatment. Ann. Intern. Med. 15, 829–839 (1941).
doi: 10.7326/0003-4819-15-5-829
Gossop, M., Johns, A. & Green, L. Opiate withdrawal: inpatient versus outpatient programmes and preferred versus random assignment to treatment. Br. Med. J. 293, 103–104 (1986).
doi: 10.1136/bmj.293.6539.103
Gowing, L., Farrell, M., Ali, R. & White, J. M. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst. Rev. 3, CD002024 (2016).
Walsh, S. L., Strain, E. C. & Bigelow, G. E. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction 98, 427–439 (2003).
pubmed: 12653813 doi: 10.1046/j.1360-0443.2003.00372.x
Ridge, G., Gossop, M., Lintzeris, N., Witton, J. & Strang, J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J. Subst. Abuse Treat. 37, 95–100 (2009).
pubmed: 19004598 doi: 10.1016/j.jsat.2008.09.007
Gold, M., Redmond, D. & Kleber, H. Clonidine in opiate withdrawal. Lancet 1, 929–930 (1978).
pubmed: 76860 doi: 10.1016/S0140-6736(78)90699-2
Sigmon, S. C. et al. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 70, 1347–1354 (2013).
pubmed: 24153411 pmcid: 4131728 doi: 10.1001/jamapsychiatry.2013.2216
World Health Organization. Essential medicines (WHO, 2017).
Bickel, W. K. et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J. Pharmacol. Exp. Ther. 247, 47–53 (1988).
pubmed: 2459370
Donny, E. C., Walsh, S. L., Bigelow, G. E., Eissenberg, T. & Stitzer, M. L. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology 161, 202–212 (2002).
pubmed: 11981600 doi: 10.1007/s00213-002-1027-0
Strain, E. C., Stitzer, M. L., Liebson, I. A. & Bigelow, G. E. Dose-response effects of methadone in the treatment of opioid dependence. Ann. Intern. Med. 119, 23–27 (1993).
pubmed: 8498759 doi: 10.7326/0003-4819-119-1-199307010-00004
Donny, E. C., Brasser, S. M., Bigelow, G. E., Stitzer, M. L. & Walsh, S. L. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100, 1496–1509 (2005).
pubmed: 16185211 doi: 10.1111/j.1360-0443.2005.01232.x
Feng, X. Q., Zhu, L. L. & Zhou, Q. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management. J. Pain. Res. 10, 1225–1239 (2017).
pubmed: 28579821 pmcid: 5449157 doi: 10.2147/JPR.S138698
Volpe, D. A., Xu, Y., Sahajwalla, C. G., Younis, I. R. & Patel, V. Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J. Pharm. Sci. 107, 2983–2991 (2018).
pubmed: 30205091 doi: 10.1016/j.xphs.2018.08.025
Meemken, L., Hanhoff, N., Tseng, A., Christensen, S. & Gillessen, A. Drug-drug interactions with antiviral agents in people who inject drugs requiring substitution therapy. Ann. Pharmacother. 49, 796–807 (2015).
pubmed: 25902733 doi: 10.1177/1060028015581848
Stringer, J., Welsh, C. & Tommasello, A. Methadone-associated QT interval prolongation and torsades de pointes. Am. J. Health Syst. Pharm. 66, 825–833 (2009).
pubmed: 19386945 doi: 10.2146/ajhp070392
Jasinski, D. R., Pevnick, J. S. & Griffith, J. D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch. Gen. Psychiatry 35, 501–516 (1978).
pubmed: 215096 doi: 10.1001/archpsyc.1978.01770280111012
Squeglia, L. M., Fadus, M. C., McClure, E. A., Tomko, R. L. & Gray, K. M. Pharmacological treatment of youth substance use disorders. J. Child Adolesc. Psychopharmacol. https://doi.org/10.1089/cap.2019.0009 (2019).
doi: 10.1089/cap.2019.0009 pubmed: 31009234
Walsh, S. L. et al. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 119, 268–276 (1995).
pubmed: 7675960 doi: 10.1007/BF02246290
Stoller, K., Bigelow, G. E., Walsh, S. L. & Strain, E. C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 154, 230–242 (2001).
pubmed: 11351930 doi: 10.1007/s002130000637
Rosado, J., Walsh, S. L., Bigelow, G. E. & Strain, E. C. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone. Drug Alcohol Depend. 90, 261–269 (2007).
pubmed: 17517480 pmcid: 2094723 doi: 10.1016/j.drugalcdep.2007.04.006
Johnson, R. E. et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. 343, 1291–1297 (2000).
doi: 10.1056/NEJM200011023431802
Hser, Y. I. et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 111, 695–705 (2016).
pubmed: 26599131 pmcid: 4801718 doi: 10.1111/add.13238
Rosenthal, R. N. et al. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA 316, 282–290 (2016).
pubmed: 27434441 doi: 10.1001/jama.2016.9382
Nasser, A. F. et al. Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. J. Clin. Psychopharmacology 36, 18–26 (2016).
doi: 10.1097/JCP.0000000000000434
US Food and Drug Administration. Sublocade. FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209819s000lbl.pdf (2017).
Lofwall, M. R. et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern. Med. 178, 764–773 (2018).
pubmed: 29799968 pmcid: 6145749 doi: 10.1001/jamainternmed.2018.1052
Eder, H. et al. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction 100, 1101–1109 (2005).
pubmed: 16042640 doi: 10.1111/j.1360-0443.2005.001128.x
Beck, T. et al. Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. Addiction 109, 617–626 (2014).
pubmed: 24304412 pmcid: 4226326 doi: 10.1111/add.12440
Meini, M. et al. Relationship between plasma concentrations of the l-enantiomer of methadone and response to methadone maintenance treatment. Eur. J. Pharmacol. https://doi.org/10.1016/j.ejphar.2015.03.081 (2015).
doi: 10.1016/j.ejphar.2015.03.081 pubmed: 25891369
Verthein, U. et al. The effects of racemic D, L-methadone and L-methadone in substituted patients-a randomized controlled study. Drug Alcohol Depend. 80, 267–271 (2005).
pubmed: 15916866 doi: 10.1016/j.drugalcdep.2005.04.007
Robertson, J. R. et al. Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: a randomized controlled trial. Addiction 101, 1752–1759 (2006).
pubmed: 17156174 doi: 10.1111/j.1360-0443.2006.01603.x
van den Brink, W. et al. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ 327, 310 (2003).
pubmed: 12907482 pmcid: 169643 doi: 10.1136/bmj.327.7410.310
Haasen, C. et al. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br. J. Psychiatry 191, 55–62 (2007).
pubmed: 17602126 doi: 10.1192/bjp.bp.106.026112
Strang, J. et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet 375, 1885–1895 (2010).
pubmed: 20511018 doi: 10.1016/S0140-6736(10)60349-2
Oviedo-Joekes, E. et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N. Engl. J. Med. 361, 777–786 (2009).
pubmed: 19692689 pmcid: 5127701 doi: 10.1056/NEJMoa0810635
Strang, J. et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br. J. Psychiatry 207, 5–14 (2015).
pubmed: 26135571 doi: 10.1192/bjp.bp.114.149195
Blanken, P., Hendriks, V. M., van Ree, J. M. & van den Brink, W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction 105, 300–308 (2010).
pubmed: 19922517 doi: 10.1111/j.1360-0443.2009.02754.x
Oviedo-Joekes, E. et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry 73, 447–455 (2016).
pubmed: 27049826 doi: 10.1001/jamapsychiatry.2016.0109
Minozzi, S. et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst. Rev. 16, CD001333 (2011).
Dunn, K. E. et al. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Exp. Clin. Psychopharmacol. 21, 74–83 (2013).
pubmed: 23205722 doi: 10.1037/a0030743
Krupitsky, E. et al. Injectable extended-release naltrexone for opioid dependence. Lancet 377, 1506–1513 (2011).
pubmed: 21529928 doi: 10.1016/S0140-6736(11)60358-9
Krupitsky, E. et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch. Gen. Psychiatry 69, 973–981 (2012).
pubmed: 22945623 pmcid: 3614358 doi: 10.1001/archgenpsychiatry.2012.1a
Lee, J. D. et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 391, 309–318 (2018).
pubmed: 29150198 doi: 10.1016/S0140-6736(17)32812-X
Larochelle, M. R. et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann. Intern. Med. 169, 137–145 (2018).
pubmed: 29913516 pmcid: 6387681 doi: 10.7326/M17-3107
Morgan, J. R., Schackman, B. R., Weinstein, Z. M., Walley, A. Y. & Linas, B. P. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug. Alcohol. Depend. 200, 34–39 (2019).
pubmed: 31082666 doi: 10.1016/j.drugalcdep.2019.02.031
Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs (SAMHSA, 2015).
National Institute for Health & Clinical Excellence. Drug misuse – psychosocial interventions (NICE, 2007).
Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug misuse and dependence: UK guidelines on clinical management (Global and Public Health, 2017).
Intstitute of Medicine. Psychosocial interventions for mental and substance use disorders: a framework for establishing evidence-based standards (National Academies Press, 2015).
Department of Health and Social Care. Drug misuse and dependence: UK guidelines on clinical management (Department of Health and Social Care, 2017).
Amato, L., Minozzi, S., Davoli, M. & Vecchi, S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst. Rev. 5, CD004147 (2011).
Weiss, R. D. et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch. Gen. Psychiatry https://doi.org/10.1001/archgenpsychiatry.2011.121 (2011).
doi: 10.1001/archgenpsychiatry.2011.121 pubmed: 22065255 pmcid: 3470422
Fiellin, D. A. et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N. Engl. J. Med. 355, 365–374 (2006).
pubmed: 16870915 doi: 10.1056/NEJMoa055255
Sigmon, S. C. et al. Interim buprenorphine vs. waiting list for opioid dependence. N. Engl. J. Med. 375, 2504–2505 (2016).
pubmed: 28002704 pmcid: 5373028 doi: 10.1056/NEJMc1610047
Schwartz, R. P. et al. A randomized controlled trial of interim methadone maintenance. Arch. Gen. Psychiatry 63, 102–109 (2006).
pubmed: 16389204 doi: 10.1001/archpsyc.63.1.102
Kelly, J. F. & Greene, M. C. The twelve promises of alcoholics anonymous: psychometric measure validation and mediational testing as a 12-step specific mechanism of behavior change. Drug Alcohol Depend 133, 633–640 (2013).
pubmed: 24004905 doi: 10.1016/j.drugalcdep.2013.08.006
Humphreys, K. & Moos, R. H. Encouraging posttreatment self-help group involvement to reduce demand for continuing care services: two-year clinical and utilization outcomes. Alcohol Clin. Exp. Res. 31, 64–68 (2007).
pubmed: 17207103 doi: 10.1111/j.1530-0277.2006.00273.x
Humphreys, K. Circles of Recovery: Self-help Organisations for Addictions (Cambridge Univ. Press, 2004).
White, W. L. Addiction recovery: its definition and conceptual boundaries. J. Subst. Abuse Treat. 33, 229–241 (2007).
pubmed: 17889295 doi: 10.1016/j.jsat.2007.04.015
White, W. L. Medication-assisted recovery from opioid addiction: historical and contemporary perspectives. J. Addict. Dis. 31, 199–206 (2012).
pubmed: 22873182 doi: 10.1080/10550887.2012.694597
Betty Ford Institute Consensus Panel. What is recovery? A working definition from the Betty Ford institute. J. Subst. Abuse Treat. 33, 221–228 (2007).
doi: 10.1016/j.jsat.2007.06.001
Gilman, S. M., Galanter, M. & Dermatis, H. Methadone anonymous: a 12-step program for methadone maintained heroin addicts. Subst. Abus. 22, 247–256 (2001).
pubmed: 12466684
Kelly, J. F., Humphreys, K. & Ferri, M. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database Syst. Rev. 9, CD012880 (2019).
Melnick, G., De Leon, G., Thomas, G., Kressel, D. & Wexler, H. K. Treatment process in prison therapeutic communities: motivation, participation, and outcome. Am. J. Drug Alcohol Abuse 27, 633–650 (2001).
pubmed: 11727881 doi: 10.1081/ADA-100107660
De Leon, G., Hawke, J., Jainchill, N. & Melnick, G. Therapeutic communities. Enhancing retention in treatment using “Senior professor” staff. J. Subst. Abuse Treat. 19, 375–382 (2000).
pubmed: 11166502 doi: 10.1016/S0740-5472(00)00124-0
Strang, J. et al. Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs 79, 1395–1418 (2019). This overview paper describes the development and application of take-home naloxone as a public health strategy to reduce fatal outcome from opioid overdose by mobilizing and enabling civilian interim emergency care with the antidote naloxone: it also considers the concentrated naloxone nasal sprays which have recently been developed in addition to the long-established injectable form of naloxone.
pubmed: 31352603 pmcid: 6728289 doi: 10.1007/s40265-019-01154-5
Ravndal, E. & Amundsen, E. J. Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study. Drug Alcohol Depend 108, 65–69 (2010).
pubmed: 20022184 doi: 10.1016/j.drugalcdep.2009.11.008
Hawk, K. & D’Onofrio, G. Emergency department screening and interventions for substance use disorders. Addict. Sci. Clin. Pract. 13, 18 (2018).
pubmed: 30078375 pmcid: 6077851 doi: 10.1186/s13722-018-0117-1
Stewart, L. M., Henderson, C. J., Hobbs, M. S., Ridout, S. C. & Knuiman, M. W. Risk of death in prisoners after release from jail. Aust. N. Z. J. Public. Health 28, 32–36 (2004).
pubmed: 15108744 doi: 10.1111/j.1467-842X.2004.tb00629.x
Lee, J. D. et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N. Engl. J. Med. 374, 1232–1242 (2016).
pubmed: 27028913 pmcid: 5454800 doi: 10.1056/NEJMoa1505409
Gordon, M. S. et al. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 142, 33–40 (2014).
pubmed: 24962326 doi: 10.1016/j.drugalcdep.2014.05.011
Hser, Y. I., Anglin, M. D., Grella, C., Longshore, D. & Prendergast, M. Drug treatment careers. A conceptual framework and existing research findings. J.Subst. Abuse Treat. 14, 543–558 (1997).
pubmed: 9437626 doi: 10.1016/S0740-5472(97)00016-0
Dennis, M. L., Scott, C. K., Funk, R. & Foss, M. A. The duration and correlates of addiction and treatment careers. J. Subst. Abuse Treat. 28 (Suppl. 1), S51–S62 (2005).
pubmed: 15797639 doi: 10.1016/j.jsat.2004.10.013
Simpson, D. D., Joe, G. W., Lehman, W. E. K. & Sells, S. B. Addiction careers: etiology, treatment, and 12-year follow-up outcomes. J. Drug. Issues 16, 107–122 (1986).
doi: 10.1177/002204268601600106
Krebs, E. et al. Estimating state transitions for opioid use disorders. Med. Decis. Mak. 37, 483–497 (2017).
doi: 10.1177/0272989X16683928
Hser, Y. I., Evans, E., Grella, C., Ling, W. & Anglin, D. Long-term course of opioid addiction. Harv. Rev. Psychiatry 23, 76–89 (2015).
pubmed: 25747921 doi: 10.1097/HRP.0000000000000052
Scott, C. K., Foss, M. A. & Dennis, M. L. Pathways in the relapse-treatment-recovery cycle over 3 years. J. Subst. Abuse Treat. 28 (Suppl. 1), S63–S72 (2005).
pubmed: 15797640 doi: 10.1016/j.jsat.2004.09.006
Gjersing, L. & Bretteville-Jensen, A. L. Patterns of substance use and mortality risk in a cohort of ‘hard-to-reach’ polysubstance users. Addiction 113, 729–739 (2018).
pubmed: 28987019 doi: 10.1111/add.14053
Hser, Y. I. et al. High mortality among patients with opioid use disorder in a large healthcare system. J. Addict. Med. 11, 315–319 (2017).
pubmed: 28426439 pmcid: 5930020 doi: 10.1097/ADM.0000000000000312
Degenhardt, L., Larney, S., Randall, D., Burns, L. & Hall, W. Causes of death in a cohort treated for opioid dependence between 1985 and 2005. Addiction 109, 90–99 (2014).
pubmed: 23961881 doi: 10.1111/add.12337
Darke, S. et al. Patterns and correlates of sustained heroin abstinence: findings from the 11-year follow-up of the australian treatment outcome study. J. Stud. Alcohol. Drugs 76, 909–915 (2015).
pubmed: 26562598 doi: 10.15288/jsad.2015.76.909
Dowell, D. et al. Contribution of opioid-involved poisoning to the change in life expectancy in the United States, 2000-2015. JAMA. 318, 1065–1067 (2017).
pubmed: 28975295 pmcid: 5818798 doi: 10.1001/jama.2017.9308
Rudd, R. A., Seth, P., David, F. & Scholl, L. Increases in drug and opioid-involved overdose deaths - United States, 2010-2015. MMWR Morb. Mortal. Wkly. Rep. 65, 1445–1452 (2016).
pubmed: 28033313 doi: 10.15585/mmwr.mm655051e1
Fischer, B., Pang, M. & Tyndall, M. The opioid death crisis in Canada: crucial lessons for public health. Lancet Public Health 4, e81–e82 (2019).
pubmed: 30579840 doi: 10.1016/S2468-2667(18)30232-9
Roxburgh, A. et al. Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug Alcohol Depend. 179, 291–298 (2017).
pubmed: 28826104 doi: 10.1016/j.drugalcdep.2017.07.018
Kimber, J., Hickman, M., Strang, J., Thomas, K. & Hutchinson, S. Rising opioid-related deaths in England and Scotland must be recognised as a public health crisis. Lancet Psychiatry 6, 639–640 (2019).
pubmed: 31201043 doi: 10.1016/S2215-0366(19)30209-3
Case, A. & Deaton, A. Mortality and morbidity in the 21(st) century. Brook. Pap. Econ. Act. 2017, 397–476 (2017).
doi: 10.1353/eca.2017.0005
Marsch, L. A. et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch. Gen. Psychiatry 62, 1157–1164 (2005).
pubmed: 16203961 doi: 10.1001/archpsyc.62.10.1157
Ward, J., Hall, W. & Mattick, R. P. Role of maintenance treatment in opioid dependence. Lancet 353, 221–226 (1999).
pubmed: 9923893 doi: 10.1016/S0140-6736(98)05356-2
Mitchell, S. G. et al. Changes in quality of life following buprenorphine treatment: relationship with treatment retention and illicit opioid use. J. Psychoact. Drugs 47, 149–157 (2015).
doi: 10.1080/02791072.2015.1014948
Nosyk, B. et al. Short term health-related quality of life improvement during opioid agonist treatment. Drug. Alcohol. Depend. 157, 121–128 (2015).
pubmed: 26511766 pmcid: 4778423 doi: 10.1016/j.drugalcdep.2015.10.009
Sadeghi, N., Davaridolatabadi, E., Rahmani, A., Ghodousi, A. & Ziaeirad, M. Quality of life of adolescents and young people arrive at an addiction treatment centers upon their admission, and 1, 4 and 8 months after methadone maintenance therapy. J. Educ. Health Promot 6, 95 (2017).
pubmed: 29114562 pmcid: 5651645 doi: 10.4103/jehp.jehp_297_13
Knudsen, H. K., Abraham, A. J. & Roman, P. M. Adoption and implementation of medications in addiction treatment programs. J. Addict. Med. 5, 21–27 (2011).
pubmed: 21359109 pmcid: 3045214 doi: 10.1097/ADM.0b013e3181d41ddb
Mayet, S., Farrell, M., Ferri, M., Amato, L. & Davoli, M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst. Rev. 25, CD004330 (2005).
Zhang, Z., Friedmann, P. D. & Gerstein, D. R. Does retention matter? Treatment duration and improvement in drug use. Addiction 98, 673–684 (2003).
pubmed: 12751985 doi: 10.1046/j.1360-0443.2003.00354.x
Levine, A. R. et al. Gender-specific predictors of retention and opioid abstinence during methadone maintenance treatment. J. Subst. Abuse Treat. 54, 37–43 (2015).
pubmed: 25795601 doi: 10.1016/j.jsat.2015.01.009
Hser, Y. I. et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 109, 79–87 (2014).
pubmed: 23961726 doi: 10.1111/add.12333
Matson, S. C., Hobson, G., Abdel-Rasoul, M. & Bonny, A. E. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic. J. Addict. Med. 8, 176–182 (2014).
pubmed: 24695018 doi: 10.1097/ADM.0000000000000035
Burns, L. et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction 110, 646–655 (2015).
pubmed: 25516077 doi: 10.1111/add.12834
Cousins, S. J., Crevecoeur-MacPhail, D., Kim, T. & Rawson, R. A. The Los Angeles county hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in los angeles county (2010-2015). J. Subst. Abuse Treat. 85, 78–83 (2018).
pubmed: 28291571 doi: 10.1016/j.jsat.2017.02.011
Kaskutas, L. A. et al. Elements that define recovery: the experiential perspective. J. Stud. Alcohol. Drugs 75, 999–1010 (2014).
pubmed: 25343658 pmcid: 4211341 doi: 10.15288/jsad.2014.75.999
White, W. L. Recovery. Alcohol. Treat. Q. 23, 3–15 (2005).
Humphreys, K. & Lembke, A. Recovery-oriented policy and care systems in the UK and USA. Drug Alcohol Rev. 33, 13–18 (2014).
pubmed: 24267515 doi: 10.1111/dar.12092
Bray, J. W. et al. Quality of life as an outcome of opioid use disorder treatment: a systematic review. J. Substance Abuse Treat. 76, 88–93 (2017).
doi: 10.1016/j.jsat.2017.01.019
Garner, B. R., Scott, C. K., Dennis, M. L. & Funk, R. R. The relationship between recovery and health-related quality of life. J. Subst. Abuse Treat. 47, 293–298 (2014).
pubmed: 25012552 pmcid: 4138291 doi: 10.1016/j.jsat.2014.05.006
Feelemyer, J. P., Jarlais, D. C. D., Arasteh, K., Phillips, B. W. & Hagan, H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review. Drug. Alcohol. Depend. 134, 251–258 (2014).
pubmed: 24200104 doi: 10.1016/j.drugalcdep.2013.10.011
Laudet, A. B. The case for considering quality of life in addiction research and clinical practice. Addict. Sci. Clin. Pract. 6, 44–55 (2011).
pubmed: 22003421 pmcid: 3188817
Strada, L., Franke, G. H., Schulte, B., Reimer, J. & Verthein, U. Development of OSTQOL: a measure of quality of life for patients in opioid substitution treatment. Eur. Addict. Res. 23, 238–248 (2017).
pubmed: 29161720 doi: 10.1159/000484239
[No authors listed]. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol. Med. 28, 551–558 (1998).
doi: 10.1017/S0033291798006667
De Maeyer, J., Vanderplasschen, W. & Broekaert, E. Quality of life among opiate-dependent individuals: a review of the literature. Int. J. Drug. Policy 21, 364–380 (2010).
pubmed: 20172706 doi: 10.1016/j.drugpo.2010.01.010
Neale, J. et al. Development and validation of ‘sure’: a patient reported outcome measure (prom) for recovery from drug and alcohol dependence. Drug Alcohol Depend 165, 159–167 (2016).
pubmed: 27344196 pmcid: 4946826 doi: 10.1016/j.drugalcdep.2016.06.006
Neale, J. et al. Emerging consensus on measuring addiction recovery: findings from a multi-stakeholder consultation exercise. Drugs Educ. Prev. Policy 23, 31–40 (2015).
doi: 10.3109/09687637.2015.1100587
Hser, Y.-I., Grella, C., Chou, C.-P. & Douglas Anglin, M. Relationships between drug treatment careers and outcomes: findings from the national drug abuse treatment outcome study. Eval. Rev. 22, 496–519 (1998).
doi: 10.1177/0193841X9802200404
Flynn, P. M., Joe, G. W., Broome, K. M., Simpson, D. D. & Brown, B. S. Recovery from opioid addiction in DATOS. J. Subst. Abuse Treat. 25, 177–186 (2003).
pubmed: 14670523 doi: 10.1016/S0740-5472(03)00125-9
Panebianco, D., Gallupe, O., Carrington, P. J. & Colozzi, I. Personal support networks, social capital, and risk of relapse among individuals treated for substance use issues. Int. J. Drug. Policy 27, 146–153 (2016).
pubmed: 26520237 doi: 10.1016/j.drugpo.2015.09.009
Muller, A. E., Skurtveit, S. & Clausen, T. Building abstinent networks is an important resource in improving quality of life. Drug Alcohol Depend 180, 431–438 (2017).
pubmed: 28988006 doi: 10.1016/j.drugalcdep.2017.09.006
Nestler, E. J. Is there a common molecular pathway for addiction? Nat. Neurosci. 8, 1445–1449 (2005).
pubmed: 16251986 doi: 10.1038/nn1578
Koob, G. F. Negative reinforcement in drug addiction: the darkness within. Curr. Opin. Neurobiol. 23, 559–563 (2013).
pubmed: 23628232 doi: 10.1016/j.conb.2013.03.011
Martin, N. K. et al. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin. Infect. Dis. 57 (Suppl. 2), S39–S45 (2013).
pubmed: 23884064 pmcid: 3722076 doi: 10.1093/cid/cit296
World Health Organization. ICD-10 classification of mental and behavioural disorders (WHO, 2016).
Koob, G. F., Everitt, B. J. & Robbins, T. W. in Fundamental Neuroscience 4th edn (eds Squire, L. R. et al.) 871–898 (Elsevier, 2013).

Auteurs

John Strang (J)

National Addiction Centre, Institute of Psychiatry Psychology & Neuroscience, King's College London, London, UK. john.strang@kcl.ac.uk.
South London & Maudsley NHS Foundation Trust, London, UK. john.strang@kcl.ac.uk.

Nora D Volkow (ND)

National Institute on Drug Abuse, National Institutes of Health, Rockville, MD, USA. nvolkow@nida.nih.gov.

Louisa Degenhardt (L)

National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia.

Matthew Hickman (M)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Kimberly Johnson (K)

Department of Mental Health Law and Policy, College of Community and Behavioural Sciences, University of South Florida, Tampa, FL, USA.

George F Koob (GF)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA.

Brandon D L Marshall (BDL)

Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA.

Mark Tyndall (M)

School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.

Sharon L Walsh (SL)

Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, KT, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH